Ebix Limited appoints three new independent directors to board
- Ebix Limited appointed Dr. Praveen Kumar Gupta, Dr. Satvir Singh Deswal, and Dr. Viney Kapoor Mehra as additional independent directors on October 6, 2026
- Three existing independent directors resigned due to health issues, family commitments, and expanded professional responsibilities
- The board reconstituted seven committees including Audit, Risk Management, and ESG to reflect the new composition
- Ravi Kumar Gupta was nominated as Chairman of subsidiary Ebix Inc., replacing Devender Kumar Garg

*this image is generated using AI for illustrative purposes only.
Ebix Limited appointed three additional non-executive independent directors on October 6, 2026. The appointments follow the resignation of three existing independent directors and aim to maintain the requisite board composition under regulatory guidelines.
The newly appointed directors are Dr. Praveen Kumar Gupta, Dr. Satvir Singh Deswal, and Dr. Viney Kapoor Mehra. Their appointment is subject to shareholder approval via a special resolution within the prescribed statutory period. The resignations of Ms. Ila Gupta, Mr. Anil Kumar, and Mr. Devender Kumar Garg were approved by the board in the same meeting held by circulation.
Board Composition and Regulatory Compliance
The changes were executed to adhere to the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced the National Company Law Tribunal (NCLT) order dated February 13, 2025, which mandated a status quo on board composition pending further orders. The board confirmed that none of the new appointees are debarred from holding office by any regulatory authority.
The resignations stemmed from personal commitments, health issues, and expanded professional responsibilities. Ms. Gupta cited family obligations and media reports concerning the company. Mr. Kumar stepped down due to increased academic duties at the University of Delhi. Mr. Garg resigned citing health concerns, specifically hypertension and diabetes.
Reconstitution of Board Committees
Consequent to the changes, the board reconstituted seven key committees: Audit, Nomination and Remuneration, Stakeholders' Relationship, Risk Management, ESG, Executive, and High-Powered Steering Committee. The revised composition ensures continued oversight across governance, risk, and operational functions.
| Committee | Chairperson | Key Members |
|---|---|---|
| Audit Committee | Ravi Kumar Gupta | Ashish Jaitly, Viney Kapoor Mehra |
| Nomination and Remuneration | Thomas Mathew | Ashish Jaitly, Ravi Kumar Gupta |
| Stakeholders' Relationship | Viney Kapoor Mehra | Ravi Kumar Gupta, Praveen Kumar Gupta |
| Risk Management | Satvir Singh Deswal | Ravi Kumar Gupta, Thomas Mathew |
| ESG Committee | Thomas Mathew | Praveen Kumar Gupta, Ashish Sharma |
| Executive Committee | Ashish Sharma | Ravi Kumar Gupta, Vikas Garg, Ashish Jaitly, Bhawna Sharma |
| High-Powered Steering | Praveen Kumar Gupta | Ravi Kumar Gupta, Ashish Sharma, Satvir Singh Deswal |
Subsidiary Board Changes
Pursuant to the Stockholders Agreement dated August 30, 2024, Ebix Limited exercised its right to nominate directors to its subsidiary, Ebix Inc. The board approved the nomination of Ravi Kumar Gupta as Director and Chairman of Ebix Inc., replacing Devender Kumar Garg. This action complies with Regulation 24(1) of the SEBI LODR Regulations.
What the Numbers Show
The simultaneous replacement of three independent directors indicates a structured effort to stabilize governance amid ongoing regulatory scrutiny. The reliance on academic and legal professionals for new appointments suggests a strategic focus on compliance, risk management, and institutional oversight rather than operational or financial expertise. The immediate reconstitution of all seven board committees highlights the urgency of restoring full governance functionality following the vacancies.
Historical Stock Returns for Artemis EBIX
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.53% | -1.11% | -16.17% | +4.62% | +4.62% | +4.62% |
How might the shift toward appointing academic and legal professionals over financial experts impact Ebix's strategic decision-making and investor confidence?
What are the potential implications of the pending NCLT order on the validity of the newly appointed directors' authority and future board actions?
Will the reconstitution of the Audit and Risk Management committees lead to changes in Ebix's internal control frameworks or disclosure practices?


































